Fexofenadine Research Articles

Antiallergical Effect of New Combined Nazal Aerodisperse System in the Conditions of Experimental Allergic Rhinitis

To assess the severity of the anti-allergic effect of the combined nasal spray in the conditions of experimental allergic rhinitis. The experiment was performed on Balb / c male mice, which reproduced ovalbumin-induced allergic rhinitis. The test-spray composition of fexofenadine hydrochloride + ammonium glycyrrhizinate in doses of 2.5 μg; 5 μg and 7.5 μg / nostril and compartion drugs: beclomethasone («Nasobec», IVAX Pharmaceuticals) and levocabastine («Tyzine® Allergy», Johnson & Johnson) in doses of 3.5 μg / nostril and 5 μg / nostril respectively, were administered intranasally after 14-day immunization of animals. On the 17th day of the experiment, the severity of nasal symptoms (sneezing and nasal grooming), the change in the concentration of histamine, IFN-γ, IL-6, IgE, and TNF-α and markers of oxidative stress (superoxide dismutase activity and concentration of malonic dialdehyde) were determined. The use of levocabastine and beclomethasone contributed to the reduction of allergic symptoms, with the most pronounced pharmacological effect observed with the administration of beclomethasone. The administration of the 5 μg of test-spray reduced nasal symptoms in mice and also contributed to a decrease in the concentration of histamine, IFN-γ, IL-6, IgE, and TNF-α, as well as the restoration of pro / antioxidant balance. At the same time, the test aerodisperse system at a dose of 5 μg was comparable to beclomethasone and exceeded levocabastine in terms of pharmacological action. The high effectiveness of the test-spray, comparable to itranasal glucocorticoids, makes this compound a promising drug corrector of allergic rhinitis.

Effect of the Fexofenadine on the expression of HRH-1 and HRH-4 receptor in Peripheral Blood Mononuclear Cell isolated from children with diagnosed allergy - in vitro study Short communication.

Fexofenadine (FXF) is the active metabolite of terfenadine with selective peripheral H1receptor antagonist activity. FXF is a third-generation antihistamine, non-sedating, rapid and very long acting used in symptoms associated with allergic diseases such as allergic rhinitis, asthma and dermatitis. The pleiotropic effects of histamine are mediated by four types of receptors that belong to the G-protein-coupled receptor family: histamine H1 receptor (HRH-1), histamine H2 receptor, histamine H3 receptor, and histamine H4 receptor. Our hypothesis is that HRH-4 opens new possibility in treatment in allergy diseases and FXF could be the antagonist of both HRH-1 and HRH-4. We isolated a peripheral blood mononuclear cell (PBMC) from children with diagnosed allergies and healthy - control group and measured the HRH-1 and HRH-4 mRNA gene expression using Quantitive Real-Time PCR. We obtained the results from basal gene expression and after FXF and histamine stimulation. HRH-1 mRNA basal gene expression shows significantly higher, and HRH-4 shows significantly lower expression in allergy group compared to control. In both groups HRH-1 mRNA gene expression was observed as statistically significant increased after histamine stimulation compared to cells not treated, while in HRH-4 only in allergy group we observed statistical increase. FXF successively blocked histamine affinity in HRH-1 mRNA gene expression but not in HRH-4, where we not observed any reaction. Results clearly overturned our hypothesis about the possibility of using FXF to block over-expression HRH-4 and open new way of treatment in allergy diseases.

An Efficient and Scalable Synthesis of Fexofenadine Hydrochloride

AbstractAllergic rhinitis (AR) is an important allergic inflammatory disease, affecting 30‐60 million people annually in the USA. The most important class of drug used in the treatment of AR is second‐generation H1‐antihistamines (highly selective and non‐sedating drugs) like levocetirizine, desloratadine and fexofenadine. Different synthetic strategies are reported for the preparation of fexofenadine hydrochloride, but these approaches involve the formation of byproducts, either toxic or difficult to remove. The aim of this work is to find a new, efficient and scalable synthetic approach for the preparation of fexofenadine hydrochloride. The final product was assembled from methyl 2‐(4‐bromophenyl)‐2‐methylpropanoate, 3‐butyn‐1‐ol and azacyclonol, cheap and commercially available raw materials. A key step allows to build the central oxygenated‐C4‐moiety through a key 5‐membered intermediate, avoiding toxic or expensive reagents and catalysts. The 8‐step synthesis is competitive with existing protocols, leading to fexofenadine hydrochloride in 59% overall yield.

Analytical Method Development and Validation for Simultaneous Estimation of some drugs in Pharmaceutical Dosage Form

A new reversed-phase high performance liquid chromatography method was developed forsimultaneous determination of Fexofenadine hydrochloride (FEXO) and Montelukast sodium (MONTE) in combined tablet formulation. Efficient separation was achieved on C18 Grace Column (4.6×250 mm, 5 um) as stationary phase comprising of Methanol and Water (70: 30, v/v) as mobile phase by using 0.05% Orthophosphoric acid of which pH Adjusted to 2.5 with flow rate 1ml/min. Detection was carried out in UV 730 D PDA detector at 241.0nm. The retention time 6.0167 min and 8.500 min approximately of FEXO and MONTE respectively. The linearity of the FEXO and MONTE was found over the range of 60μg/mL to 300μg/mL and 5μg/mL to 25μg/mL. The developed method was accurate, precise, economic, fast, and selective. The method gives good resolution for drugs. By using above method, FEXO & MONTE were separated with good peaks, minimum tailing, good retention time, resolution time between peak were sufficient. Hence this method was suitable and finalized.

Noradrenergic modulation of stopping impulsivity in cocaine use disorder

Drug transporters and CYP enzymes are important sources of pharmacokinetics (PK) variability in drug responses and can cause various pharmacological and toxicological consequences, leading to either toxicity or an insufficient pharmacological effect. In recent years, the cocktail approach was developed to determine in vivo CYP and transporters activities, but these approaches are somewhat limited. We described the development and validation of three sensitive and specific LC–MS/MS assays for the determination of P-gp and major human CYP isoenzyme activities following oral administration of a drug cocktail of subtherapeutic doses (lower than 10 times) of caffeine (CAF), omeprazole (OME), losartan (LOS), midazolam (MDZ), metoprolol (METO) and fexofenadine (FEX) in healthy volunteers. The three validated methods were selective for all tested analytes. No interference or matrix effect was observed for the mass transition and retention times for all compounds monitored. Additionally, assays were linear over a wide range, and limits of quantification varied between 0.01–5 ng/mL plasma. The coefficients of variation obtained in the precision studies and the inter- and intra-assay accuracies were less than 15%, guaranteeing the reproducibility and repeatability of the results. All substrates and metabolites were stable in plasma during freeze-thaw cycles. Three healthy volunteers were selected based on genotyping for CYP2C9, CYP2C19 and CYP2D6. One volunteer was genotyped as an extensive metabolizer (EM) for all tested CYP isoforms, one volunteer was genotyped as a poor metabolizer (PM) for the CYP2C9 isoform (CYP2C9*3/*3), and one volunteer was genotyped as a PM for the CYP2D6 isoform (CYP2D6*4/*4). The methods allowed the quantification of all analytes over the entire sampling period (12 h) in all studied genotypes. Thus, the analytical methods described here were sufficiently sensitive for use in low-dose pharmacokinetic studies.

Synergistic enantioseparation systems with either cyclodextrins or cyclofructans and L-alanine Tert butyl ester lactate.

The combined use of chiral ionic liquids (CILs) and conventional chiral selectors (CSs) in CE, to establish a synergistic system, has proven to be an effective approach for the separation of enantiomeric pairs. In this study, a new CE method was developed, employing a binary system of a CS, either a cyclodextrin (CD) or a cyclofructan (CF), and a chiral amino acid ester-based ionic liquid (AAIL), for the chiral separation of four basic, acidic and zwitterionic drug compounds. In particular, the enantioseparation of two anticoagulants, warfarin (WAR) and coumachlor (COU), a non-opioid analgesic, nefopam (NEF) and a third-generation antihistamine, fexofenadine (FXD), was examined, by supporting the BGE with a CS and the chiral AAIL L-alanine tert butyl ester lactate (L-AlaC4 Lac). Parameters, such as the type of the CS, the concentration of both the CS and L-AlaC4 Lac, and the BGE pH, were methodically examined in order to optimize the chiral separation of each analyte. It was observed that, in some cases, the addition of the AAIL into the BGE improved both resolution (Rs ) and efficiency (N) significantly. In other cases, the synergistic effect enabled baseline separation of analyte enantiomers, at a much lower concentration of the CS. Finally, after optimization of separation conditions, baseline separations (Rs >1.5) of all four analytes were achieved in less than 5min.

Development and Validation of UV-Spectrophotometric and RP-HPLC Methods for Simultaneous Estimation of Fexofenadine Hydrochloride, Montelukast Sodium and Ambroxol Hydrochloride in Tablet Dosage Form

A UV-spectrophotometric and RP-HPLC method was developed and validated for concurrent estimation of fexofenadine hydrochloride (FEX), montelukast sodium (MLK) and ambroxol hydrochloride (AMB). In RP-HPLC chromatography, the retention time for FEX, MLK and AMB was 2.775 min, 9.529 min and 5.261 min, respectively and detection at λmax 210 nm for all three of drugs (overlain spectra). Linear regression analysis shows a good linear relationship; in the concentration range of 10-30, 10-50 and 5-25 μg/mL; for FEX, MLK and AMB with r2 > 0.999. The UV-spectrophotometric estimation was done by two methods; zero order and first derivative method. These methods were based on the measurement of absorbance at 220.20, 283.42 and 245.84 nm in zero order; 221, 287.52 and 262.25 nm in first order derivative method. In both UV methods, the drugs follow the Beer-Lambert's law in the concentration range of 6-26, 4-24 and 8-28 μg/mL, respectively showing correlation coefficient r2 > 0.999. The RP-HPLC and UV methods showed good reproducibility and recovery with the percent relative standard deviation (RSD) less than 5%. These methods were successfully applied for reliable quantification of FEX, MLK and AMB in a commercial and routine analysis in combined dosage form.

LC-MS/MS analysis of the plasma concentrations of a cocktail of 5 cytochrome P450 and P-glycoprotein probe substrates and their metabolites using subtherapeutic doses

Drug transporters and CYP enzymes are important sources of pharmacokinetics (PK) variability in drug responses and can cause various pharmacological and toxicological consequences, leading to either toxicity or an insufficient pharmacological effect. In recent years, the cocktail approach was developed to determine in vivo CYP and transporters activities, but these approaches are somewhat limited. We described the development and validation of three sensitive and specific LC–MS/MS assays for the determination of P-gp and major human CYP isoenzyme activities following oral administration of a drug cocktail of subtherapeutic doses (lower than 10 times) of caffeine (CAF), omeprazole (OME), losartan (LOS), midazolam (MDZ), metoprolol (METO) and fexofenadine (FEX) in healthy volunteers. The three validated methods were selective for all tested analytes. No interference or matrix effect was observed for the mass transition and retention times for all compounds monitored. Additionally, assays were linear over a wide range, and limits of quantification varied between 0.01–5 ng/mL plasma. The coefficients of variation obtained in the precision studies and the inter- and intra-assay accuracies were less than 15%, guaranteeing the reproducibility and repeatability of the results. All substrates and metabolites were stable in plasma during freeze-thaw cycles. Three healthy volunteers were selected based on genotyping for CYP2C9, CYP2C19 and CYP2D6. One volunteer was genotyped as an extensive metabolizer (EM) for all tested CYP isoforms, one volunteer was genotyped as a poor metabolizer (PM) for the CYP2C9 isoform (CYP2C9*3/*3), and one volunteer was genotyped as a PM for the CYP2D6 isoform (CYP2D6*4/*4). The methods allowed the quantification of all analytes over the entire sampling period (12 h) in all studied genotypes. Thus, the analytical methods described here were sufficiently sensitive for use in low-dose pharmacokinetic studies.

TITRIMETRIC ASSAY OF SOME ANTIHISTAMINE DRUGS WITH PYRIDINIUM FLUORO CHROMATE (PFC) REAGENT

In the present paper, simple, convenient accurate, precise and cost effective titrimetric (Visual volumetric) method has been reported for the estimation of some antihistamine drugs e.g. Cyproheptadine hydrochloride (CPH), Fexofenadine hydrochloride (FFH), Promethazine hydrochloride (PMH) and Pheniramine maleate (PM) in pure form and in their pharmaceutical preparations such as Ciplactin (Tab), Allegra (Tab), Phenergan (Tab and Inj) and Avil (Tab and Inj) with Pyridinium fluoro chromate (PFC) reagent. The principle of this method is based on the fact, that each pharmaceutical drug consists of certain organic functional group which on oxidation by a known excess of potassium iodate in sulphuric acid medium followed by iodometric titration in presence of reagent Pyridinium fluoro chromate (PFC) establishes stoichiometric relationship between drug molecule and an oxidising reagent Pyridinium fluoro chromate (PFC).Different results obtained for each drug during experiment, has been validated by different statistical parameters such as percentage error, standard deviation (SD) and coefficient of variation (CV).Results obtained from these statistical parameters proves the accuracy and precision of adopted method.

A Validated RP-HPLC Method and Force Degradation Studies of Fexofenadine Hydrochloride in Pharmaceutical Dosage Form

A stability indicating HPLC method was developed and validated for the quantitative determination of fexofenadine hydrochloride. An isocratic separation was achieved using phenomenex (C18) column (250×4.6 mm, 5 μm) with flow rate of 1.0 ml/min and UV detection at 254 nm. The mobile phase consists of 5Mm acetate buffer: acetonitrile (50:50; v/v) with pH 9.4 adjusted with acetic acid. The drug was subjected to oxidative, acidic, basic, neutral, photolytic and thermal degradation. All degradation products were eluted in an overall analytical run time of approximately 40 min with the parent compound fexofenadine hydrochloride at a flow rate of approximately 3.3±0.3 min. The method was linear over the concentration range of 31.5-500 μg/ml (r2 = 0.999) with limit of detection and quantification of 3.5 μg/ml and 10.1 μg/ml, respectively. The method has the requisite accuracy, selective, precision and robustness to assay fexofenadine HCl in tablets.Dhaka Univ. J. Pharm. Sci. 17(1): 43-50, 2018 (June)

Design and preparation of controlled floating gastroretentive delivery systems for enhanced fexofenadine hydrochloride oral bioavailability

Purpose: To design and prepare effervescent floating gastroretentive tablets for controlledfexofenadine hydrochloride (HCl) release and enhanced oral bioavailability.Method: Various tablet formulations of the drug were prepared by direct compression. A systematic approach in the design of the formulations was adopted, where, first, formulations consisting of single polymers with a high polymer : sodium bicarbonate ratio were investigated for its physicochemical properties (in-vitro floating behaviour, drug release profile, etc). Next, improvement of tablets’ properties was achieved by decreasing polymer : sodium bicarbonate ratio. Subsequently, a final optimization step involved blending polymers at different polymer : polymer ratios. The formulations were evaluated in vitro and in vivo in albino rabbitsResults: The formulation consisting of hydroxypropyl methylcellulose K15M/hydroxypropylmethyl cellulose K100LV at 1 : 2 ratio (F8) showed good floating properties (14 s floating lag time) with nearly zero order controlled drug release for 24 h (R2 = 0.9876). In-vivo bioavailability studies of F8 in albino rabbits showed a significant increase in area under the curve (AUC, 134 %, p < 0.05) and hence an improvement in its oral bioavailability, compared to a commercial conventional product.Conclusion: The good quality of the effervescent floating gastroretentive tablets of fexofenadine HCl developed is an indication that the approach used is suitable for the formulation of the drug for controlled drug release and enhanced oral bioavailabiliy.Keywords: Effervescent, Floating, Gastroretentive, Fexofenadine, Bioavailability

Dual targeting agents for Aβ plaque/P-glycoprotein and Aβ plaque/nicotinic acetylcholine α4β2* receptors-potential approaches to facilitate Aβ plaque removal in Alzheimer's disease brain.

Alzheimer's disease (AD) affects 10% of people older than 65 and is characterized by a progressive loss of cognitive function with an abnormal accumulation of amyloid β (Aβ ) plaques and neurofibrillary tangles (NFT) in the brain. Efforts to reduce brain Aβ plaques continue to be investigated as a therapeutic approach for AD. We report here development of dual targeting agents with affinity for Aβ plaque/P-glycoprotein (Pgp) and Aβ plaque/α4β 2* nicotinic acetylcholine receptors (nAChR). These novel dual agents may be able to efflux Aβ plaques via the paravascular (glymphatic) pathways. Ferulic acid (FA), ferulic acid ethyl ester (FAEE), and curcumin (CUR) were used for Aβ plaques, fexofenadine (FEX) was used as substrate for Pgp and nifrolidine (NIF) was used for α4β 2* nAChRs. Aβ plaque/α4β 2* nAChR dual agent, FA-NIF (GKS-007) exhibited IC50 = 3-6 nM for α4β 2* nAChRs in [3H]cytisine-radiolabeled thalamus and frontal cortex in rat brain slices. In postmortem human AD frontal cortex, Aβ plaques labeled with [3H]PIB, FEX-CUR showed a 35% reduction in gray matter (GM)/white matter (WM) [3H]PIB binding, while CUR alone showed a 50% reduction. In vivo biodistribution studies are required of the Aβ-Pgp and Aβ-α4β 2* nAChRs dual targeting agents in order to evaluate their potential as therapeutic approaches for reducing brain Aβ plaques.

Effects of antihistamines on the H295R steroidogenesis – Autocrine up-regulation following 3β-HSD inhibition

Millions of people of all ages suffer from allergies worldwide and as a consequence antihistamines are among the most commonly prescribed pharmaceuticals in the world. We investigated the disruptive effects of three antihistamines, promethazine (PMZ), cetirizine (CET) and fexofenadine (FEX) on the H295R steroidogenesis. A multi-steroid LC-MS/MS method was used to quantify 13 steroid hormones in the steroidogenesis. In addition, real-time RT-PCR was used to determine if exposure to antihistamines altered gene expression in the cell line. When exposing the H295R cells to PMZ and CET, significant increases in Δ5-steroids and significant decreases in Δ4-steroids were observed, indicating an inhibition of 3β-hydroxysteroid dehydrogenase (3β-HSD). A sequential decrease in corticosteroids, androgens and estrogens were also observed. Overall, FEX had no effect on the steroidogenesis even though minor effects were observed at the highest concentrations. Real-time RT-PCR showed that PMZ resulted in significant up-regulation of 3β-HSD and 17β-HSD, whereas CET only resulted in up-regulation of 3β-HSD. This indicated that the decrease in steroids downstream from 3β-HSD following PMZ and CT exposure induced a compensatory autocrine response in 3β-HSD gene expression. The effects on the steroidogenesis were observed at concentrations 30–50 times higher than the therapeutic plasma concentrations. However, antihistamines are lipophilic and may accumulate in adrenals and gonads. Thus, disruptive effects of PMZ and CET on human steroidogenesis cannot be excluded.

Application of Bromate-Bromide Mixture as a Green Brominating Agent for the Determination of Fexofenadine Hydrochloride in Pharmaceutical Dosage Form

Application of Bromate-Bromide Mixture as a Green Brominating Agent for the Determination of Fexofenadine Hydrochloride in Pharmaceutical Dosage Form

Effect of Sodium Starch Glycolate on Formulation of Fexofenadine Hydrochloride Immediate Release Tablets by Direct Compression Method

Present study aspires at the design of an immediate release formulation with prospective use of fexofenadine hydrochloride by exploring the effect of sodium starch glycolate as super disintegrant. Fexofenadine hydrochloride immediate release tablets (Formulations F-1, F-2, F-3, F-4 and F-5) using different ratios of sodium starch glycolate as a disintegrant were prepared by direct compression method. Standard physicochemical tests were performed for all the formulations. Dissolution studies of the formulations were done in phosphate buffer, pH 6.8 using USP apparatus II (paddle apparatus) at 50 rpm. Percent release of fexofenadine hydrochloride of formulations F-1, F-2, F-3, F-4 and F-5 were 89.98%, 90.98%, 92.95, 96.92% and 99.85%, respectively after 1 h and the release pattern followed the zero order kinetics. The release rate in the formulation F-5 was higher compared to other formulations and the studied market products. Sodium starch glycolate speed up the release of the drug from the core tablets, and the release of fexofenadine hydrochloride from tablets was directly proportional to the amount of sodium starch glycolate present in the formulations and there by produced immediate action.

Actual use trial of Allegra FX, fexofenadine hydrochloride, for Japanese pollen allergy patients in OTC setting

Actual use trial of Allegra FX, fexofenadine hydrochloride, for Japanese pollen allergy patients in OTC setting

Crisis of unexpected abnormal behaviors after administration of fexofenadine hydrochloride / pseudoephedrine hydrochloride combination drug in the treatment of allergic rhinitis for the patients with severe motor and intellectual disabilities.

Crisis of unexpected abnormal behaviors after administration of fexofenadine hydrochloride / pseudoephedrine hydrochloride combination drug in the treatment of allergic rhinitis for the patients with severe motor and intellectual disabilities.

Sorption of citalopram, irbesartan and fexofenadine in soils: Estimation of sorption coefficients from soil properties

The sorption of 3 pharmaceuticals, which may exist in 4 different forms depending on the solution pH (irbesartan in cationic, neutral and anionic, fexofenadine in cationic, zwitter-ionic and anionic, and citalopram cationic and neutral), in seven different soils was studied. The measured sorption isotherms were described by Freundlich equations, and the sorption coefficients, KF (for the fixed n exponent for each compound), were related to the soil properties to derive relationships for estimating the sorption coefficients from the soil properties (i.e., pedotransfer rules).The largest sorption was obtained for citalopram (average KF value for n = 1 was 1838 cm3 g−1) followed by fexofenadine (KF = 35.1 cm3/n μg1−1/n g−1, n = 1.19) and irbesartan (KF = 3.96 cm3/n μg1−1/n g−1, n = 1.10). The behavior of citalopram (CIT) in soils was different than the behaviors of irbesartan (IRB) and fexofenadine (FEX). Different trends were documented according to the correlation coefficients between the KF values for different compounds (RIRB,FEX = 0.895, p-value<0.01; RIRB,CIT = −0.835, p-value<0.05; RFEX,CIT = −0.759, p-value<0.05) and by the reverse relationships between the KF values and soil properties in the pedotransfer functions. While the KF value for citalopram was positively related to base cation saturation (BCS) or sorption complex saturation (SCS) and negatively correlated to the organic carbon content (Cox), the KF values of irbesartan and fexofenadine were negatively related to BCS, SCS or the clay content and positively related to Cox. The best estimates were obtained by combining BCS and Cox for citalopram (R2 = 93.4), SCS and Cox for irbesartan (R2 = 96.3), and clay content and Cox for fexofenadine (R2 = 82.9).

Formulation and evaluation of fexofenadine hydrochloride orally disintegrating tablets for pediatric use

Allergic rhinitis is a common disease in children which has considerable negative effects on the quality of life. Fexofenadine hydrochloride (FFH) is a second-generation oral antihistamine which has been widely perscribed for alleviating symptoms of AR in children. The aim of this study was to take the advantage of convenient direct compression method for preparation of Orally Disintegrating Tablets (ODTs) containing 30 mg FFH per tablet. Six ready-to-use commercial tablet excipients (F-Melt®, Pearlitol® Flash, Pharmaburst® 500, Prosolv® Easytab SP, Ludiflash®, Parteck® ODT®) were used for direct compression and suitability of these excipients were evaluated. ODTs could be successfully compressed with all the investigated excipients and all of the formulations exhibited acceptable crushing stregth, low friability and remarkably short disintegration time. The ODTs which were able to possess a disintegration time below 30 s were considered eligible for further studies. In vitro dissolution studies showed a complete release of the drug from ODTs made from Pharmaburst® 500 within 15 min. Short term stability results exhibited no significant change of the drug in tested formulations. In conclusion, FFH containing ODTs formulated with Pharmaburst® 500 were determined explicitly the most promising formulation when compressed at a force of 1000 kg.

Effect of compound glycyrrhizin combined with fexofenadine hydrochloride in the treatment of chronic urticaria and its influence on plasma histamine

Objective To investigate the effect of compound glycyrrhizin combined with fexofenadine hydrochloride in the treatment of chronic urticaria and its effect on plasma histamine. Methods 100 patients with chronic urticaria were selected as study objects, and they were divided into the control group(50 cases) and observation group(50 cases) according to the random number table method.The control group was treated with fexofenadine hydrochloride, while the observation group was treated with compound glycyrrhizin on the basis of the control group.The clinical effect and plasma histamine level were compared between the two groups. Results The effective rate of the observation group was 96.0%, which was significantly higher than 84.0% of the control group(χ2=7.951, P<0.05). After treatment, the plasma histamine content of the observation group was (2.38±0.26)ng/mL, which was lower than (3.10±0.29)ng/mL of the control group, and the difference between the two groups was statistically significant(t=6.084, P<0.05). Conclusion The compound glycyrrhizin combined with fexofenadine hydrochloride in the treatment of chronic urticaria can reduce the symptoms of the patients, reduce the number and size of the patients and effectively control the clinical symptoms of the patients.And it can effectively reduce the level of plasma histamine in patients with good clinical effect and application value, it is worth to be promoted in clinical. Key words: Urticaria; Histamine; Compound glycyrrhizin; Fexofenadine hydrochloride